David Meyers
Cardiovascular Disease · Chesterfield, MONPI 1225045719
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 169 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,134 and has fallen 97.3% since, to $31 in 2025.
Across 169 payments — averaging $18.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$398
- Boehringer Ingelheim$361
- Boston Scientific$323
- Amgen$237
- AstraZeneca$230
- Actelion Pharmaceuticals US, Inc.$185
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,131100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 25 | $398 |
| Boehringer Ingelheim | 18 | $361 |
| Boston Scientific | 5 | $323 |
| Amgen | 8 | $237 |
| AstraZeneca | 16 | $230 |
| Actelion Pharmaceuticals US, Inc. | 14 | $185 |
| Novartis | 16 | $182 |
| Abbott | 1 | $172 |
| Amarin Pharma, Inc. | 12 | $145 |
| United Therapeutics Corporation | 7 | $129 |
| Pfizer | 8 | $120 |
| Electromed, Inc. | 5 | $78 |
| Regeneron Healthcare Solutions, Inc. | 4 | $74 |
| Kowa Pharmaceuticals America, Inc. | 5 | $64 |
| Sunovion Pharmaceuticals Inc. | 3 | $60 |
| Sanofi | 2 | $44 |
| Grifols USA, LLC | 2 | $36 |
| Genentech USA, Inc. | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Advanced Respiratory, Inc | 2 | $31 |
| Abiomed | 1 | $31 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $31 |
| GSK | 2 | $27 |
| AbbVie | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Merck | 1 | $16 |
| Bioventus LLC | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Inari Medical, Inc. | 1 | $12 |
| Mylan Specialty L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIENCE SKYPOINT$172
- WATCHMAN Access System$139
- Repatha$122
How this compares
$3,131 in reported general payments places this provider in the 60th percentile of 391 cardiovascular disease providers in Missouri.
Other cardiovascular disease in Chesterfield
- James EllisonChesterfield$267K
- Glenn DavisonChesterfield$118K
- Edward HurleyChesterfield$19K
- Keith MankowitzChesterfield$16K
- Mikhail KosiborodKansas City$1.1M
- Georges ChahoudSaint Louis$937K
- William BowenSaint Louis$726K
- Daniel KellySaint Louis$582K
- John SpertusKansas City$360K
- James FairlambColumbia$342K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.